As a clinician scientist, I am heavily involved in the UK's clinical trials programme for ALL and am chief investigator of UKALL14 and UKALL60+, the UK's frontline academically-initiated trials for ALL. My research lab programme takes advantage of the opportunity to do translational work arising from these trials - we have a range of projects which examine basic aspects of ALL biology in various models. Another goal in the lab is the development of attenuated oncolytic measles virus as a therapy for ALL. We are specifically interested in the mechanistic aspects of how measles virus kills cancer cells leaving non-transformed cells relatively unharmed. We are also investigating on how measles virus interacts with the immune system during cancer treatment. Our projects are funded by Leukaemia and Lymphoma Research and CR UK.